Abstract
The use of donor human milk to provide therapeutic benefit to infants should only proceed where there is positive ‘value’. This can be determined through an assessment of the benefit and the known risks. The emergence of new products derived from human milk requires new value assessments. The known hazards in human milk are modified by differences in the donor selection, processing methods and intended use and result in a unique risk assessment where any of these factors vary. The human source of the raw product requires high ethical standards in the design of these services with care taken to protect donors and recipients from harm. Any supplement to maternal milk should be provided cautiously to avoid displacement of maternal lactation.
| Original language | English |
|---|---|
| Article number | 151157 |
| Journal | Seminars in Perinatology |
| Volume | 43 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 1 Nov 2019 |
Fingerprint
Cite this
}
Benefit by design : Determining the ‘value’ of donor human milk and medical products derived from human milk in NICU. / Hartmann, Ben T.
In: Seminars in Perinatology, Vol. 43, No. 7, 151157, 01.11.2019.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Benefit by design
T2 - Determining the ‘value’ of donor human milk and medical products derived from human milk in NICU
AU - Hartmann, Ben T.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - The use of donor human milk to provide therapeutic benefit to infants should only proceed where there is positive ‘value’. This can be determined through an assessment of the benefit and the known risks. The emergence of new products derived from human milk requires new value assessments. The known hazards in human milk are modified by differences in the donor selection, processing methods and intended use and result in a unique risk assessment where any of these factors vary. The human source of the raw product requires high ethical standards in the design of these services with care taken to protect donors and recipients from harm. Any supplement to maternal milk should be provided cautiously to avoid displacement of maternal lactation.
AB - The use of donor human milk to provide therapeutic benefit to infants should only proceed where there is positive ‘value’. This can be determined through an assessment of the benefit and the known risks. The emergence of new products derived from human milk requires new value assessments. The known hazards in human milk are modified by differences in the donor selection, processing methods and intended use and result in a unique risk assessment where any of these factors vary. The human source of the raw product requires high ethical standards in the design of these services with care taken to protect donors and recipients from harm. Any supplement to maternal milk should be provided cautiously to avoid displacement of maternal lactation.
KW - Best practice
KW - Bioethics
KW - Donor Human Milk Banking
UR - http://www.scopus.com/inward/record.url?scp=85073124676&partnerID=8YFLogxK
U2 - 10.1053/j.semperi.2019.06.005
DO - 10.1053/j.semperi.2019.06.005
M3 - Review article
VL - 43
JO - Seminars in Perinatology
JF - Seminars in Perinatology
SN - 0146-0005
IS - 7
M1 - 151157
ER -